IQVIA (NYSE:IQV) Earns Overweight Rating from Analysts at Stephens

Stephens initiated coverage on shares of IQVIA (NYSE:IQV) in a research note released on Friday, Marketbeat Ratings reports. The firm issued an overweight rating and a $250.00 price objective on the medical research company’s stock.

Several other research firms also recently issued reports on IQV. Truist Financial reduced their price objective on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. JPMorgan Chase & Co. cut their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. BTIG Research lowered their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Barclays cut their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, Evercore ISI lowered their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $255.82.

IQVIA Trading Up 3.0 %

Shares of NYSE IQV opened at $197.27 on Friday. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a 50-day moving average of $208.90 and a two-hundred day moving average of $223.32. The company has a market cap of $35.80 billion, a PE ratio of 25.89, a P/E/G ratio of 2.05 and a beta of 1.49.

Hedge Funds Weigh In On IQVIA

Several institutional investors have recently modified their holdings of IQV. Simplify Asset Management Inc. lifted its stake in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after buying an additional 3,894 shares in the last quarter. Versor Investments LP bought a new stake in IQVIA in the 3rd quarter valued at $1,328,000. CIBC Asset Management Inc boosted its stake in IQVIA by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock worth $62,501,000 after purchasing an additional 8,490 shares during the period. Sequoia Financial Advisors LLC increased its holdings in IQVIA by 17.5% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 75,054 shares of the medical research company’s stock worth $17,785,000 after purchasing an additional 11,170 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in shares of IQVIA by 3.9% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,023,264 shares of the medical research company’s stock valued at $242,483,000 after purchasing an additional 38,307 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.